The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL)
暂无分享,去创建一个
D. Sasseville | T. Kupper | Youwen Zhou | I. Litvinov | E. Netchiporouk | K. Pehr | Brenda Cordeiro | L. Moreau | M. Gilbert | Marc-André Doré | Martin Gilbert
[1] D. Risser,et al. Identification of geographic clustering and regions spared by cutaneous T‐cell lymphoma in Texas using 2 distinct cancer registries , 2015, Cancer.
[2] D. Sasseville,et al. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines , 2014, Cell cycle.
[3] R. Mahato,et al. Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. , 2014, Biomaterials.
[4] A. MacLeod,et al. Skin-Resident T Cells Sense Ultraviolet Radiation–Induced Injury and Contribute to DNA Repair , 2014, The Journal of Immunology.
[5] J. Olsen,et al. B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL) , 2014, Leukemia.
[6] D. Sasseville,et al. Thymocyte selection-associated high mobility group box gene (TOX) is aberrantly over-expressed in mycosis fungoides and correlates with poor prognosis , 2014, Oncotarget.
[7] D. Sasseville,et al. Ectopic Expression of Cancer–Testis Antigens in Cutaneous T-cell Lymphoma Patients , 2014, Clinical Cancer Research.
[8] S. Horwitz,et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. , 2014, Journal of the American Academy of Dermatology.
[9] S. Horwitz,et al. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions. , 2014, Journal of the American Academy of Dermatology.
[10] S. Leibundgut-Landmann,et al. IL-17 regulates systemic fungal immunity by controlling the functional competence of NK cells. , 2014, Immunity.
[11] B. Dulmage,et al. Lessons learned from gene expression profiling of cutaneous T‐cell lymphoma , 2013, The British journal of dermatology.
[12] M. Nykter,et al. Cancer genome sequencing: understanding malignancy as a disease of the genome, its conformation, and its evolution. , 2013, Cancer letters.
[13] M. Weinstock,et al. Changing incidence trends of cutaneous T-cell lymphoma. , 2013, JAMA dermatology.
[14] J. Scarisbrick,et al. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. , 2013, European journal of cancer.
[15] D. Sasseville,et al. Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma. , 2013, Blood.
[16] T. Litman,et al. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma , 2013, Cell cycle.
[17] Y. Tada,et al. Association of nerve growth factor, chemokine (C-C motif) ligands and immunoglobulin E with pruritus in cutaneous T-cell lymphoma. , 2013, Acta dermato-venereologica.
[18] D. Sasseville,et al. Loss of BCL7A expression correlates with poor disease prognosis in patients with early-stage cutaneous T-cell lymphoma , 2013, Leukemia & lymphoma.
[19] Y. Tada,et al. Increased CCL18 expression in patients with cutaneous T‐cell lymphoma: association with disease severity and prognosis , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.
[20] D. Sasseville,et al. The role of AHI1 and CDKN1C in cutaneous T‐cell lymphoma progression , 2012, Experimental dermatology.
[21] James J. Campbell,et al. Human Anti-CCR4 Minibody Gene Transfer for the Treatment of Cutaneous T-Cell Lymphoma , 2012, PloS one.
[22] R. Willemze,et al. A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides. , 2012, The Journal of investigative dermatology.
[23] Wei Wei,et al. Long-term Outcomes of 1,263 Patients with Mycosis Fungoides and Sézary Syndrome from 1982 to 2009 , 2012, Clinical Cancer Research.
[24] M. Martinka,et al. Molecular markers of early-stage mycosis fungoides. , 2012, The Journal of investigative dermatology.
[25] D. Jarrossay,et al. Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β , 2012, Nature.
[26] Y. Tada,et al. IL-22, but Not IL-17, Dominant Environment in Cutaneous T-cell Lymphoma , 2011, Clinical Cancer Research.
[27] C. Geisler,et al. Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway. , 2011, The Journal of investigative dermatology.
[28] L. van der Fits,et al. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome. , 2011, The Journal of investigative dermatology.
[29] J. Scarisbrick,et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Michael A McDevitt,et al. Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation , 2010, Leukemia & lymphoma.
[31] James J. Campbell,et al. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. , 2010, Blood.
[32] D. Sasseville,et al. Transcriptional Profiles Predict Disease Outcome in Patients with Cutaneous T-Cell Lymphoma , 2010, Clinical Cancer Research.
[33] R. Kurzrock,et al. Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. , 2009, Journal of the American Academy of Dermatology.
[34] B. Dallapiccola,et al. Array‐based comparative genomic hybridization in early‐stage mycosis fungoides: Recurrent deletion of tumor suppressor genes BCL7A, SMAC/DIABLO, and RHOF , 2008, Genes, chromosomes & cancer.
[35] A. J. Wilson,et al. Immune Function Abnormalities in Peripheral Blood Mononuclear Cell Cytokine Expression Differentiates Stages of Cutaneous T-Cell Lymphoma/Mycosis Fungoides , 2008, Clinical Cancer Research.
[36] Stefano Monti,et al. Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. , 2007, Blood.
[37] Nicola Pimpinelli,et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). , 2007, Blood.
[38] M. Weinstock,et al. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. , 2007, Archives of dermatology.
[39] F. Prósper,et al. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. , 2007, Blood.
[40] F. V. Van Dolah,et al. Microarray validation: factors influencing correlation between oligonucleotide microarrays and real-time PCR , 2006, Biological Procedures Online.
[41] J. Pedrosa,et al. Cutting Edge: IFN-γ Regulates the Induction and Expansion of IL-17-Producing CD4 T Cells during Mycobacterial Infection1 , 2006, The Journal of Immunology.
[42] Malik Yousef,et al. Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. , 2006, Blood.
[43] Remco Dijkman,et al. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] Nicola Pimpinelli,et al. WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.
[45] M. Feinmesser,et al. Familial mycosis fungoides: report of 6 kindreds and a study of the HLA system. , 2005, Journal of the American Academy of Dermatology.
[46] E. Tartour,et al. Expression and activity of IL‐17 in cutaneous T‐cell lymphomas (mycosis fungoides and sezary syndrome) , 2004, International journal of cancer.
[47] T. Waldmann,et al. Interleukin-2 receptor-directed therapies for cutaneous lymphomas. , 2003, Hematology/oncology clinics of North America.
[48] S. Sealfon,et al. Focused microarray analysis. , 2003, Methods.
[49] Stephen M. Hewitt,et al. Post-analysis follow-up and validation of microarray experiments , 2002, Nature Genetics.
[50] L. Medeiros,et al. Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. , 2002, Blood.
[51] F. Speleman,et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.
[52] T. Teesalu,et al. Epithelial V-like Antigen (EVA), a Novel Member of the Immunoglobulin Superfamily, Expressed in Embryonic Epithelia with a Potential Role as Homotypic Adhesion Molecule in Thymus Histogenesis , 1998, The Journal of cell biology.
[53] E. Zabarovsky,et al. Cloning of two candidate tumor suppressor genes within a 10 kb region on chromosome 13q14, frequently deleted in chronic lymphocytic leukemia , 1997, Oncogene.
[54] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[55] B. Thiers. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) , 2008 .
[56] P. Hazen,et al. Hodgkin's disease and mycosis fungoides in a married couple. , 1977, Dermatologica.